These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30426671)

  • 21. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
    Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
    Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin's lymphoma.
    Rogasch JMM; Hundsdoerfer P; Hofheinz F; Wedel F; Schatka I; Amthauer H; Furth C
    BMC Cancer; 2018 May; 18(1):521. PubMed ID: 29724189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.
    Hutchings M; Loft A; Hansen M; Pedersen LM; Buhl T; Jurlander J; Buus S; Keiding S; D'Amore F; Boesen AM; Berthelsen AK; Specht L
    Blood; 2006 Jan; 107(1):52-9. PubMed ID: 16150944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
    Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
    J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Gene Expression-based Model to Predict Metabolic Response After Two Courses of ABVD in Hodgkin Lymphoma Patients.
    Luminari S; Donati B; Casali M; Valli R; Santi R; Puccini B; Kovalchuk S; Ruffini A; Fama A; Berti V; Fragliasso V; Zanelli M; Vergoni F; Versari A; Rigacci L; Merli F; Ciarrocchi A
    Clin Cancer Res; 2020 Jan; 26(2):373-383. PubMed ID: 31645353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
    Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
    J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone.
    Markova J; Kahraman D; Kobe C; Skopalova M; Mocikova H; Klaskova K; Dedeckova K; Eich HT; Böll B; Dietlein M; Kozak T
    Leuk Lymphoma; 2012 Jan; 53(1):64-70. PubMed ID: 21740300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDG PET in response evaluation of bulky masses in paediatric Hodgkin's lymphoma (HL) patients enrolled in the Italian AIEOP-LH2004 trial.
    Lopci E; Mascarin M; Piccardo A; Castello A; Elia C; Guerra L; Borsatti E; Sala A; Todesco A; Zucchetta P; Farruggia P; Cistaro A; Buffardi S; Bertolini P; Bianchi M; Moleti ML; Bunkheila F; Indolfi P; Fagioli F; Garaventa A; Burnelli R;
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):97-106. PubMed ID: 30219963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma.
    Cuccaro A; Annunziata S; Cupelli E; Martini M; Calcagni ML; Rufini V; Giachelia M; Bartolomei F; Galli E; D'Alò F; Voso MT; Leone G; Giordano A; Larocca LM; Hohaus S
    Cancer Med; 2016 Mar; 5(3):398-406. PubMed ID: 26758564
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Hassan A; Siddique M; Bashir H; Riaz S; Wali R; Mahreen A; Nawaz MK
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1198-1206. PubMed ID: 28229191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Semiquantitative analysis of interim
    Ribeiro T; Marques A; Ferreira G; Castro C; Tavares M; Espírito-Santo A; Moreira C; Mariz J
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(5):281-286. PubMed ID: 34425968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of rs12917 MGMT Polymorphism on [
    Kewitz-Hempel S; Kurch L; Cepelova M; Volkmer I; Sauerbrey A; Conrad E; Knirsch S; Pöpperl G; Steinbach D; Beer AJ; Kramm CM; Sahlmann CO; Erdlenbruch B; Reinbold WD; Odparlik A; Sabri O; Kluge R; Staege MS
    Mol Imaging Biol; 2019 Dec; 21(6):1182-1191. PubMed ID: 30945122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
    Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
    J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined prognostic role of TARC and interim
    Husi K; Pinczés LI; Fejes Z; Nagy B; Illés Á; Miltényi Z
    Hell J Nucl Med; 2022; 25(2):125-131. PubMed ID: 35913858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.
    Kostakoglu L; Goldsmith SJ; Leonard JP; Christos P; Furman RR; Atasever T; Chandramouly A; Verma S; Kothari P; Coleman M
    Cancer; 2006 Dec; 107(11):2678-87. PubMed ID: 17063502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
    Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
    AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis.
    Adams HJ; Kwee TC
    Ann Hematol; 2016 Apr; 95(5):695-706. PubMed ID: 26931115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas.
    Barrington SF; Kluge R
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):97-110. PubMed ID: 28411336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?
    Spaepen K; Stroobants S; Dupont P; Thomas J; Vandenberghe P; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
    Br J Haematol; 2001 Nov; 115(2):272-8. PubMed ID: 11703321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.